Table 2.
Antipsychotic treatment before starting clozapine in 38 patients with PD psychosis.
| Case no. | Previous AP pretreatment (max. daily dose) | Response to QUE | Switch from QUE to CLO |
|---|---|---|---|
| 1 | QUE 425 | Poor | 425–100 mg |
| 2 | None | Poor | No |
| 3 | QUE 150 | No | 150–50 mg |
| 4 | QUE 275 | Poor | 150–37.5 mg |
| 5 | QUE 100 | No | 100–25 mg |
| 6 | QUE 150 | Moderate | 150–50 mg |
| 7 | QUE 150 | Moderate | 150–50 mg |
| 8 | QUE 150 | Poor | 150–50 mg |
| 9 | QUE 150 | Poor | 150–50 mg |
| 10 | QUE 150 | Poor | 150–50 mg |
| 11 | QUE 25 | No | 25–12.5 mg |
| 12 | QUE 500 | No | 200–50 mg |
| 13 | QUE 25 | Worsening | No |
| 14 | QUE 150 | Poor | 150–50 mg |
| 15 | QUE 200 | Transient | 200–50 mg |
| 16 | QUE 100 | No | No |
| 17 | TIA 200, QUE 25 | No | 25–25 mg |
| 18 | QUE 100 | No | 100–25 mg |
| 19 | OLA 2.5, QUE 150, | No | 150–50 mg |
| 20 | HAL 10, RIS 1, QUE 150 | Transient | 150–50 mg |
| 21 | QUE 200 | Moderate | 200–50 mg |
| 22 | QUE 200 | Moderate | 100–25 mg |
| 23 | 2.5 OLA, 80 PRO, QUE 150 | Moderate | Within days |
| 24 | 100 QUE, HAL 5 | Transient | 100–25 mg |
| 25 | QUE 100 | Poor | 100–37.5 mg |
| 26 | QUE 100 | Transient | 100–25 mg |
| 27 | QUE 100 | Poor, moderate later on | 100–25 mg |
| 28 | QUE 200 | Transient | 200–50 mg |
| 29 | QUE 150 | No | 150–50 mg |
| 30 | QUE 150 | Moderate | 150–50 mg |
| 31 | RIS 1.5, QUE 150 | Transient | 150–50 mg |
| 32 | QUE 250 | Moderate | 250–50 mg |
| 33 | QUE 25, RIS 0.5 | Poor | 25 QUE and 0.5 RIS to 25 mg |
| 34 | QUE 50 | No | 50–12.5 mg |
| 35 | QUE 275 | Transient | 275–50 mg |
| 36 | QUE 150 | Poor | 150–50 mg |
| 37 | QUE 112,5 | Transient | 112.5–6.25 mg |
| 38 | QUE 100 | Poor | 50–25 mg |
Abbreviations: AP, antipsychotic; HAL, haloperidol; OLA, olanzapine; PD, Parkinson's disease; PRO, prothipendyl; QUE, quetiapine; RIS, risperidone; TIA, tiapride.